Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,209.00 -11.28 (-0.92%)

Official Closing Price Updated: 4:10 PM EDT, Aug 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Simplify's PINK or iShares' IYH: Which Healthcare ETF Should Long-Term Investors Choose Right Now? ↗

Today 15:54 EDT

Active management and a charitable mission drive Simplify's 42% gain, but iShares offers lower costs and higher dividend income for conservative investors.

Via The Motley Fool

Topics ETFs

Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or Simplify's Actively Managed PINK? ↗

Today 15:16 EDT

Fidelity's broad, low-cost index approach goes head-to-head with an actively managed, mission-driven healthcare fund.

Via The Motley Fool

Topics ETFs

Eli Lilly's GLP-1 Pricing Problem Is Actually a Growth Opportunity ↗

Today 14:20 EDT

The stock continues to look unstoppable.

Via The Motley Fool

Eli Lilly (NYSE:LLY) Shows a Strong Technical Breakout Setup ↗

August 12, 2026

Via Chartmill

Eli Lilly (NYSE:LLY) Pairs High Growth Momentum with a Defined Breakout Setup ↗

August 10, 2026

Via Chartmill

Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating? ↗

Today 13:20 EDT

It's yet another setback for the drugmaker.

Via The Motley Fool

IYH vs. FBT: Broad Healthcare ETF or Concentrated Biotech Play? ↗

Today 8:25 EDT

FBT delivered 57.7% returns over one year but with nearly double the maximum drawdown. IYH offers lower costs and steadier performance for risk-averse investors.

Via The Motley Fool

Topics ETFs

Eli Lilly (LLY) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

Revenue surged 48% on Mounjaro and Zepbound demand, with full-year guidance raised.

Via The Motley Fool

Topics Earnings

VanEck Pharmaceutical ETF vs. Invesco Biotech ETF: Which Fund Fits Your Investing Style? ↗

August 12, 2026

VanEck targets established pharma giants with lower costs and volatility, while Invesco pursues high-growth biotech companies. One delivered stronger returns; the other weathered downturns better.

Via The Motley Fool

Topics ETFs

Eli Lilly Escalates Retatrutide Fight, Reports 200-Plus Illegal Sellers to Authorities ↗

August 12, 2026

Eli Lilly filed six lawsuits against U.S. entities for illegally selling unapproved retatrutide, warning consumers of serious health risks.

Via Benzinga

Topics Law Enforcement Lawsuit

1 Vanguard ETF That Outperforms the S&P 500 and Still Has Room to Run ↗

August 12, 2026

It has proven to be a market-beater in more years than not.

Via The Motley Fool

Topics ETFs Stocks

The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For

August 12, 2026

News Provided by USA News Group on behalf of Conexeu Sciences Inc.

From USA News Group

Via GlobeNewswire

5 Revealing Analyst Questions From Eli Lilly’s Q2 Earnings Call

August 12, 2026

Eli Lilly’s second quarter was marked by a positive market reaction, despite the company missing Wall Street’s revenue expectations. Management credited grow...

Via StockStory

Topics Earnings

Better Buy: Eli Lilly vs. Novo Nordisk ↗

August 11, 2026

Novo Nordisk is playing catch-up in the GLP-1 race.

Via The Motley Fool

Absci Q2 Earnings Call Highlights ↗

August 11, 2026

Absci (NASDAQ:ABSI) outlined progress in its clinical program for ABS-201, a prolactin receptor-targeting antibody being studied for pattern hair loss and planned for development in endometriosis,...

Via MarketBeat

Topics Artificial Intelligence Earnings

2 Stocks I Think Are Hands-Down Better Picks Than SpaceX Right Now ↗

August 11, 2026

SpaceX has attractive prospects, but the market has already factored that into its share price.

Via The Motley Fool

Topics Initial Public Offering

Omada Health Touts Record Q2 as GLP-1 Demand Fuels Growth Strategy ↗

August 11, 2026

Omada Health (NASDAQ:OMDA) highlighted record second-quarter revenue and margin performance at the Canaccord Genuity Growth Conference, while outlining its strategy to expand across cardiometabolic...

Via MarketBeat

2 S&P 500 Stocks with Exciting Potential and 1 We Ignore

August 11, 2026

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...

Via StockStory

Topics Stocks

Why Eli Lilly Topped the Market Today ↗

August 10, 2026

One of its more popular products just got the green light from a major national regulator.

Via The Motley Fool

Eli Lilly Upgraded, Best Buy Downgraded: Updated Rankings on Top Blue-Chip Stocks ↗

August 10, 2026

During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start.

Via InvestorPlace

Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics? ↗

August 08, 2026

It's not much of a rivalry yet.

Via The Motley Fool

iShares Global Healthcare ETF vs State Street SPDR Biotech ETF. Which Healthcare-Focused Fund Will Bring You Profits in 2026 and Beyond? ↗

August 08, 2026

XBI surged 80% in one year but endured a 54% drawdown, while IXJ delivered steadier gains with half volatility and a 1.4% dividend.

Via The Motley Fool

Topics ETFs

Eli Lilly and Company Q2 Earnings Call Highlights ↗

August 08, 2026

Eli Lilly and Company (NYSE:LLY) reported 48% revenue growth in the second quarter of 2026, driven primarily by continued demand for its cardiometabolic medicines MOUNJARO and ZEPBOUND, while raising...

Via MarketBeat

Topics Earnings

Vanguard Health Care ETF vs State Street XLV: Which ETF Is the Better Buy for Investors in 2026? ↗

August 08, 2026

XLV's concentrated 60-stock portfolio beat VHT's broader 423 holdings over five years, though VHT delivered stronger 1-year returns.

Via The Motley Fool

Topics ETFs Economy

Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem ↗

August 07, 2026

Can anyone take the top spot away from Eli Lilly in the anti-obesity area?

Via The Motley Fool

Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound ↗

August 07, 2026

Berobenatide is one of the keys to Pfizer's future.

Via The Motley Fool

Jim Cramer Calls This Industrial Stock ‘Sensational’ And Ameriprise Financial ‘Fantastic’ ↗

August 07, 2026

Jim Cramer praises Lockheed Martin and Ameriprise Financial, advises against Cipher Digital. Eli Lilly to acquire AtaiBeckley for $3.8B.

Via Benzinga

Every S&P 500 Sector ETF Ranked by How Much It Actually Depends on Just 3 Stocks ↗

August 07, 2026

Sector ETFs give the impression of diversification. Most of them don't have it.

Via The Motley Fool

Topics Artificial Intelligence ETFs Stocks

Prediction: This Unstoppable Vanguard ETF Will Crush the S&P 500 in the Remainder of 2026 ↗

August 07, 2026

Some of America's largest growth stocks had a sluggish start to 2026, but they're bouncing back.

Via The Motley Fool

Topics Artificial Intelligence ETFs Stocks

Why Is Everyone Talking About Novo Nordisk? ↗

August 06, 2026

The drugmaker continues to face headwinds.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.